Business
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the t
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"text","content":"Joshua Hare","length":11,"tagName":"p"},{"type":"image","alt":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron","displaySize":"","headline":null,"caption":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":109,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/f7a2ba21ee9ad9d0faddab0a429da6e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GiloV_.I1LiY.7J9ReDotg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f7a2ba21ee9ad9d0faddab0a429da6e8","width":109,"height":119}}},{"type":"list","items":[{"val":[{"type":"text","content":"Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborations","length":239,"tagName":"p"}]},{"val":[{"type":"text","content":"Corporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 ","length":171,"tagName":"p"}]},{"val":[{"type":"text","content":"Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company’s on-going business development activities","length":186,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":596,"olType":false},{"type":"text","content":"MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and ch...